Zions Bancorporation’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-18
Closed -$452 892
2024
Q2
$452 Sell
18
-79
-81% -$2.24K ﹤0.01% 893
2024
Q1
$2.9K Buy
97
+9
+10% +$264 ﹤0.01% 811
2023
Q4
$2.8K Sell
88
-50
-36% -$1.57K ﹤0.01% 800
2023
Q3
$4.87K Buy
138
+2
+1% +$76 ﹤0.01% 729
2023
Q2
$5.17K Sell
136
-17
-11% -$678 ﹤0.01% 724
2023
Q1
$5.78K Sell
153
-245
-62% -$9.42K ﹤0.01% 720
2022
Q4
$16.9K Buy
398
+223
+127% +$9.19K ﹤0.01% 602
2022
Q3
$6K Buy
175
+22
+14% +$772 ﹤0.01% 760
2022
Q2
$5K Sell
153
-1,931
-93% -$62.6K ﹤0.01% 852
2022
Q1
$75K Sell
2,084
-250
-11% -$8.58K 0.01% 451
2021
Q4
$92K Sell
2,334
-380
-14% -$15.8K 0.01% 389
2021
Q3
$119K Buy
2,714
+380
+16% +$17.1K 0.01% 348
2021
Q2
$95K Buy
2,334
+19
+0.8% +$733 0.01% 355
2021
Q1
$76K Buy
2,315
+1,717
+287% +$64.6K 0.01% 369
2020
Q4
$24K Buy
598
+24
+4% +$897 ﹤0.01% 522
2020
Q3
$21K Buy
574
+349
+155% +$12.6K ﹤0.01% 523
2020
Q2
$8K Buy
225
+10
+5% +$273 ﹤0.01% 672
2020
Q1
$5K Sell
215
-108
-33% -$2.41K ﹤0.01% 697
2019
Q4
$7K Hold
323
﹤0.01% 767
2019
Q3
$7K Buy
+323
New +$6.36K ﹤0.01% 748

Other funds holding GMAB

Zions Bancorporation's GMAB Position: Q3 2024 in Review

Zions Bancorporation sold out of Genmab (GMAB) in Q3 2024, closing a stake of 18 shares — an estimated $452 sold.

Zions Bancorporation first reported a position in GMAB in Q3 2019 and held it in 20 quarters. The position peaked at $119K in Q3 2021. 224 funds tracked by Wall St. Rank hold GMAB as of Q3 2024.

  • Zions Bancorporation reported no remaining Genmab position as of Q3 2024 after selling out during the quarter.
  • Zions Bancorporation sold 18 Genmab shares in Q3 2024, an estimated $452.
  • Zions Bancorporation first reported a position in Genmab in Q3 2019 and held it in 20 quarters.
  • Zions Bancorporation's Genmab position peaked at $119K in Q3 2021.
  • 224 funds tracked by Wall St. Rank held Genmab as of Q3 2024.

Based on Zions Bancorporation's 13F filing for Q3 2024, filed 6 Nov 2024.